Catalyst Event

Merck and Co Inc (MRK) · Other

From Akros U.S. Tech 100 Protective Allocation Monthly Index (A100PAM)

6/9/2026, 12:00:00 AM

OtherSentiment: Negative

Merck and partner Gilead Sciences announced they are halting the Phase 3 EVOKE-03 trial on 2026-06-09; importance is estimated at Medium due to high expectations for Keytruda combination therapies, expected.

Korean Translation

2026-06-09 3상 EVOKE-03 임상 중단 발표. 키트루다 병용 요법에 대한 높은 기대치를 고려할 때 약 5% 이상의 부정적 영향이 예상되어 Medium으로 분류함, 예상됨.

Related Recent Events

View Full Timeline